May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Intravitreal Triamcinolone Acetonide Suppresses Concanavalin–A Induced Posterior Eye Segment Inflammation and Retinal Blood Barrier Breakdown
Author Affiliations & Notes
  • H. Yageta
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • K. Kawai
    Ophthalmology, Tokai University School of Medicine, Isehara, Japan
  • R. Yamagishi
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • M. Yamada
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • M. Watanabe
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • Y. Fukaya
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • A. Naito
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • E. Shirasawa
    Sagami Research Laboratories, Wakamoto Pharmceutical CO., Ltd., Ashigarakami–gun, Japan
  • Footnotes
    Commercial Relationships  H. Yageta, None; K. Kawai, None; R. Yamagishi, None; M. Yamada, None; M. Watanabe, None; Y. Fukaya, None; A. Naito, None; E. Shirasawa, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4269. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Yageta, K. Kawai, R. Yamagishi, M. Yamada, M. Watanabe, Y. Fukaya, A. Naito, E. Shirasawa; Intravitreal Triamcinolone Acetonide Suppresses Concanavalin–A Induced Posterior Eye Segment Inflammation and Retinal Blood Barrier Breakdown . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4269.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Concanavalin A (ConA) is a potent mitogen, which elicits vascular and retinal degeneration, breakdown of the blood–retinal barrier (BRB), and induces posterior eye segment inflammation subsequent to intravitreal injection. Recently the corticosteroid triamcinolone acetonide (TA) has become available for treatment of macular edema, diabetic retinopathy and retinal vein occlusion. It has been suggested that these types of retinal edema occur as the consequence of the breakdown of BRB. Accordingly, we evaluated the anti–inflammatory effect of intravitreal TA in an animal model of posterior eye segment inflammation.

Methods: : ConA (10, 30, 100 µg/eye) or vehicle (sterile saline) was injected intravitreally in the anesthetized male Dutch rabbit, to induce posterior eye segment inflammation. Thirty microliters of TA in a sterile saline suspension was injected into the vitreous (0.3, 1.2, 2.4 mg/eye) two days before. Seven days after ConA injection measurement of protein concentration in the vitreous body assessed BRB breakdown. Furthermore, we also compared the efficacy of TA with other steroids in lessening inflammation.

Results: : ConA injection elicited dose–dependent increases in vitreal protein over a range from 2.1, 5.3, and 6.9 mg/mL compared with the contralateral eye injected with 0.2 mg/mL of vehicle. Moreover, TA intravitreal injection before inflammation induction dose–dependently suppressed the protein increase in the vitreous body caused by 30 µg/eye ConA injection. The largest declines in protein concentration following 2.4 mg/eye TA treatment exceeded 80%.

Conclusions: : TA treatment ameliorated ConA induced inflammation and increases in vitreal protein concentration. Therefore, it appears that TA intravitreal injection is an effective approach to treat posterior eye segment inflammation associated with retinal edema resulting from BRB breakdown.

Keywords: retinitis • corticosteroids • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×